11:33 AM EDT, 04/28/2025 (MT Newswires) -- Revolution Medicines ( RVMD ) shares rose 5.9% in recent Monday trading after the company said initial data from the Phase 1 trial of zoldonrasib, a treatment for KRAS G12D mutant non-small cell lung cancer, "demonstrates acceptable safety and tolerability and encouraging initial antitumor activity in patients."

"These data reinforce the clinical potential of zoldonrasib following the initial tolerability and antitumor activity reported late last year in patients with pancreatic ductal adenocarcinoma," Revolution Medicines ( RVMD ) Chief Executive Officer Mark Goldsmith said Sunday in a statement.

The most common adverse events observed in in at least 10% of the patients were nausea, diarrhea, vomiting and rash, the company said.

Preliminary antitumor activity assessments in efficacy-evaluable patients showed an objective response rate of 61% and a disease control rate of 89%, the company said.

Price: 41.06, Change: +2.29, Percent Change: +5.91